BiotechTube
SparX Biopharmaceutical

SparX Biopharmaceutical

Cambridge, United States· Est.
sparxbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $30M

Overview

SparX Biopharmaceutical is a private, clinical-stage biotech pioneering next-generation antibody therapies for oncology. The company has built an integrated platform for antibody discovery and development, featuring proprietary technologies like SAILING™ for antibody discovery and SYNMAB™ for multispecifics, and has advanced its lead bispecific antibody, SPX-303, into Phase 1 trials. With a strategic research agreement with Mitsubishi Tanabe Pharma America and internal cGMP manufacturing capabilities, SparX is positioned to develop novel therapies that stimulate both innate and adaptive immunity, though it faces significant risks common to early-stage drug development.

Oncology

Technology Platform

Proprietary platforms for antibody discovery and engineering: SAILING™ (integrated antibody discovery), SYNMAB™ (multispecific antibody design), and a Bifunctional ADC Platform for creating next-generation antibody-drug conjugates with high specificity and activity.

Funding History

2
Total raised:$30M
Series A$25M
Seed$5M

Opportunities

The growing immuno-oncology market presents a major opportunity for novel agents like SPX-303 that target complementary immune pathways beyond PD-1/PD-L1.
The renaissance in ADC technology also creates a significant window for SparX's bifunctional ADC platform to develop best-in-class conjugates with improved therapeutic indices.

Risk Factors

The company faces high clinical risk as its lead, first-in-class asset is in early-stage trials, and its proprietary technology platforms are unproven in late-stage development.
As a pre-revenue private company, it is also dependent on external financing and partnership deals to fund operations and advance its pipeline.

Competitive Landscape

SparX operates in the highly competitive fields of immuno-oncology and ADCs, competing against large pharmaceutical companies with extensive resources and numerous biotech startups pursuing similar bispecific and next-generation ADC strategies. Differentiation will depend on demonstrating superior clinical efficacy or safety from its novel target combinations and platform-engineered constructs.

More companies in Biologics / Biosimilars →More companies in United States →